SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

FHTX

Foghorn Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7d 19h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The reported profit is entirely from a non-recurring catch-up adjustment; the underlying operating loss (ex-catch-up) was approximately $15.9M. Monitor the 10-Q for details on the restructuring and the timeline for the I&I and EP300 programs, as these are the key value drivers.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$2.04
T+0 close · Nov 9, 2026 · via day close
Latest settled
−12.25%
T+5 · $1.79
Vs SPY
−10.56%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $2.04entry
  2. T+1 · 7d ago −6.86%α −6.49% · $1.90
  3. T+5 · 20h ago −12.25%α −10.56% · $1.79
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Foghorn Therapeutics reported Q3 2026 net income of $58.2M, driven by a $74.1M cumulative catch-up adjustment in collaboration revenue from the decision to not advance two partnered programs. The company has $156.2M in cash with runway into H2 2029, but the core business remains pre-revenue and the reported profit is non-recurring. Consensus estimates were not met on an operating basis.

Key Financial Metrics

EPS
$0.80
est −$0.25 · +420.0%
Revenue
$83.5M
est $7.1M · +1076.7% · +924.7% YoY
Rating
beat

Key Facts

  • Net income of $58.2M vs net loss of $15.8M in Q3 2025, driven by $74.1M cumulative catch-up adjustment in collaboration revenue
  • Collaboration revenue of $83.5M vs $8.2M in Q3 2025, primarily from the catch-up adjustment
  • Cash, cash equivalents and marketable securities of $156.2M, providing runway into H2 2029
  • R&D expenses decreased to $18.8M from $20.0M; G&A expenses decreased to $5.8M from $6.7M
  • Restructuring costs of $2.3M incurred in Q3 2026
  • Preclinical programs advancing: oral I&I program targeting IND in 2027, Selective EP300 degrader targeting IND in 2027
  • Diluted EPS of $0.80 vs consensus estimate of ($0.25), but this is GAAP profit from non-recurring revenue

Financial Impact

Net income of $58.2M vs consensus loss of ~$15.8M; collaboration revenue of $83.5M vs consensus $7.1M, but $74.1M is a one-time catch-up adjustment

revenuenet incomecash position

Risk Factors

  • Reported profitability is non-recurring; core operating loss continues
  • Preclinical programs have not yet entered clinical trials; no near-term revenue catalysts
  • Restructuring costs and program discontinuation signal pipeline prioritization

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
63% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398284

Track record

9 reports on FHTX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +31.85% at T+5 after the Oct 1, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $1.81 Now $1.79 −0.83% settles Dec 15
  2. Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $2.04 Now $1.79 −12.25% settles Dec 8
  3. Oct 5, 20266w ago 3 Neutral 2/10 Entry $1.97 to $2.12 Now $1.79 −9.14% ▲ +7.36% +10.26% vs SPY
  4. Oct 5, 20266w ago SC 13G/A Neutral 4/10 Entry $1.97 to $2.13 Now $1.79 −9.14% ▲ +8.12% +11.30% vs SPY
  5. Oct 1, 20266w ago 8-K Bearish 7/10 Entry $2.92 to $2.09 Now $1.79 +38.70% ▲ +28.42% +29.13% vs SPY
  6. Aug 6, 202614w ago 8-K Mixed 5/10 Entry $5.57 to $4.87 Now $1.79 −67.86% ▼ −12.57% −13.17% vs SPY
  7. May 7, 202627w ago 8-K Neutral 3/10 Entry $4.20 to $3.64 Now $1.79 −57.38% ▼ −13.33% −16.47% vs SPY
  8. Apr 21, 202629w ago Press Release Bullish 7/10 Entry $5.39 to $3.60 Now $1.79 −66.79% ▼ −33.21% −36.38% vs SPY
  9. Apr 21, 202629w ago 8-K Bullish 7/10 Entry $5.39 to $3.60 Now $1.79 −66.79% ▼ −33.21% −36.38% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026